A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial

Hepatology

Volumn 37, Issue 1, 2003, Pages 182-191

  Wong, Florence ^a   Blei, Andres T ^b   Blendis, Laurence M ^a   Thuluvath, Paul J ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LIXIVAPTAN; SODIUM; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; ASCITES; BLOOD PRESSURE; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUID INTAKE; FREE WATER CLEARANCE; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; MALE; MEASUREMENT; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM INTAKE; THIRST; URINE VOLUME; VASOPRESSIN BLOOD LEVEL;

EID: 0037223321     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50021     Document Type: Article

References (33)

1. Schrier RW. Pathogenesis of sodium and water in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. N Engl J Med 1988;319:1065-1072.
2. Anderson RJ. Hospital associated hyponatremia. Kidney Int 1986;29:1237-1247.
3. Arieff AI. Effects of water, electrolyte and acid-base disorders on the central nervous system. In: Arieff AI, ed. Fluid, Electrolyte and Acid-Base Disorders. New York: Churchill Livingstone, 1985:969-1040.
4. Salerno D, DelBo A, Maggi A, Marabini M, Maffi M, Borroni GM, Moser P. Vasopressin release and water metabolism in patients with cirrhosis. J Hepatol 1994;21:822-830.
5. Gines A, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard J-F, Martin P-Y, Schrier RW. Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology 1998;28:851-864.
6. Pruszczynski W, Vahanian A, Ardaillou R, Acar J. Role of anti-diuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metabol 1984;58:599-605.
7. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Int Med 1982;96:413-417.
8. Earley LE, Sanders CA. The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low serum osmolality. J Clin Invest 1959;38:545-550.
9. Lolait SJ, O'Carroll A-M, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992;357:336-339.
10. Palm C, Gross P. V2-vasopressin receptor antagonists - Mechanism of effect and clinical implications in hyponatremia. Nephrol Dial Transplant 1999;14:2559-2562.
11. Laszlo FA, Laszlo F, DeWied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991;43:73-108.
12. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998;449:439-443.
13. Coupet J, Mazandarani H, Albright JD, Dusza JP. Characterization of VPA-985 as a specific, non-peptide vasopressin V2 antagonist [Abstract]. Proceedings of the World Congress of Neurophysial Hormones. 1997. Montreal, Canada.
14. Rolls BJ, Wood RJ, Rolls ET, Lind H, Lind W, Ledingham JG. Thirst following water deprivation in humans. Am J Physiol 1980;239:R476-R482.
15. Arroyo V, Rodes J, Gutierrez Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256.
16. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996;156:1814-1820.
17. Saxon LA, Stevenson WG, Middlekauff HR, Fonarow G, Woo M, Moser D, Stevenson LW. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1993;72:62-65.
18. Arroyo V, Claria J, Salo J, Jimenez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58.
19. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998;449:415-426.
20. Bosch-Marce M, Jimenez W, Angeli P, Leivas A, Claria J, Graziotto A, Arroyo V, Rivera F. Aquaretic effects of the k-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995;109:217-223.
21. Hamon G, Jouquey S. Effects of subchronic administration of niravoline, a novel aquaretic compound, on water and electrolyte renal excretion in cirrhotic rats. Br J Pharmacol 1996;117(Suppl 2):24P.
22. Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D. Aquaretic effects of niravoline, a k-opioid agonist, in patients with cirrhosis. J Hepatol 2000;32:38-42.
23. Naitoh M, Suzuki H, Murakami M, et al. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-H2254.
24. Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effects of long-term treatment with selective V1 and V2 receptor antagonists on the development of heart failure in rats. J Cardiovasc Pharmacol 1996;27:275-282.
25. Abraham WT, Oren RM, Crisman TS, Robertson AD, Shaker S, Lowes BD, Panther L, et al. Effects of an oral, nonpeptide, selective V2 receptor antagonist in patients with chronic heart failure. Am Coll Cardiol 1997;2(Suppl A):169A.
26. Jimenez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, et al. Long-term aquaretic efficacy of a selective nonpeptide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 2000;295:83-90.
27. Tsuboi Y, Ishihawa SE, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994;46:237-244.
28. Gerbes AL, Gulberg V, Decaux G, Gross P, Massien C, Djian J. VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis - A double-blind placebo controlled multicenter trial [Abstract]. Hepatology 1999;30:419A.
29. Albright JD, Reich MF, Delos Santos EG, Dusza JP, Sum FW, Venkatesan AM, Coupet J, et al. 5-Fluoro-2-methyl-N-[5H-pyrrolo[2,1-c]-[1,4] benzodiazepin-10911 H-ylcarbonyl)-3-chlorophenyl] benzamide (VPA-985): An orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;14:2442-2444.
30. Guyader D, Ellis-Grosse EJ, Burke JT, Orcyk GP. Dynamic effects of a novel, nonpeptide ADH (V2) antagonist in cirrhotic patients with ascites [Abstract]. Hepatology 1998;28:559A.
31. Shimizu K. Aquaretic effects of the non-peptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int 1995;48:220-226.
32. Steiner M, Philips PA. Renal tubular vasopressin receptors down-regulated by dehydration. Am J Physiol 1988;254:C404-C410.
33. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986;314:1535-1542.